Latano-Vision Sine (Latanoprost)

Latanoprost is a prostaglandin analog used in the management of glaucoma and ocular hypertension.

• Open-angle glaucoma: reduces intraocular pressure to slow disease progression.
• Ocular hypertension: lowers elevated eye pressure to prevent development of glaucoma.
• Secondary open-angle glaucoma: assists in controlling pressure when caused by other ocular conditions.

• Latanoprost binds to prostaglandin F (FP) receptors in the ciliary body, activating a cascade that remodels the extracellular matrix and enhances uveoscleral outflow of aqueous humor. The increased outflow reduces intraocular pressure, helping to protect the optic nerve from pressure‑related damage.

Latanoprost may cause ocular and systemic reactions, most of which are mild and reversible.

Common Side Effects

• Eye redness: mild conjunctival hyperemia.
• Increased eyelash growth: longer, thicker lashes.
• Iris darkening: gradual brownish pigmentation.
• Eye irritation: burning or stinging sensation.
• Blurred vision: transient visual disturbance.
• Foreign body sensation: feeling of grit in the eye.

Serious or Rare Side Effects

• Severe allergic reaction: swelling, rash, or difficulty breathing.
• Uveitis: inflammation of the uveal tract.
• Macular edema: fluid accumulation in the central retina.
• Paradoxical increase in intraocular pressure.
• Corneal edema: swelling of the cornea affecting clarity.

Before initiating therapy, clinicians should evaluate patient history and monitor ocular health.

• Baseline IOP assessment: record intraocular pressure prior to treatment.
• Iris pigmentation monitoring: observe for color changes over time.
• History of uveitis: avoid use if active inflammation is present.
• Ocular infection caution: defer treatment until infection resolves.
• Hypersensitivity screening: discontinue if allergic signs appear.
• Store at room temperature: keep in original container, protect from moisture and light.

Latanoprost may interact with other ocular or systemic agents, affecting efficacy or safety.

Major Interactions (Avoid)

• Concurrent use with other prostaglandin analog eye drops: may increase risk of ocular irritation.
• Simultaneous administration of ocular anesthetics: can exacerbate corneal toxicity.
• Use with systemic carbonic anhydrase inhibitors: may lead to excessive IOP reduction.

Moderate Interactions (Monitor Closely)

• Combination with beta‑blocker eye drops: monitor for additive IOP‑lowering effect.
• Co‑administration with non‑steroidal anti‑inflammatory eye drops: may reduce prostaglandin activity.
• Use with systemic corticosteroids: watch for delayed wound healing after ocular surgery.